Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCT, BCMA CAR-T, and GPRC5D/CD3 BiTEs in Ultra-High-Risk Multiple Myeloma
NCT07106710Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Aug 2025
- Primary completion
- Aug 2027
- Modality
- CAR-T Cells, Bispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BCMA-CAR-T and GPRC5D/CD3 bispecific T-cell engager (Institute of Hematology & Blood Diseases Hospital) in multiple myeloma (MM), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Sustained Minimal Residual Disease Negative Rate at 2 years and Minimal Residual Disease Negativity Rate at 2 years. Started Aug 2025; status: recruiting.
02
Drugs
BCMA-CAR-TGPRC5D/CD3 bispecific T-cell engager (Institute of Hematology & Blood Diseases Hospital)
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07106710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07106710.